Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on IBS-C (Oct 2019)

Posted by Matt Breese on Oct 4, 2019

Find me on:

According to our recent payer coverage analysis for irritable bowel syndrome with constipation (IBS-C) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for IBS-C treatments shows that under the pharmacy benefit, more than 42% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-IBS-C_3Q2019-finalData snapshot as of Q3 2019

Trends: In September 2019, the FDA approved Ardelyx, Inc.'s Ibsrela (tenapanor) for the treatment of IBS-C in adults.   

To read the full Reality Check on IBS-C treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing